A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)

TAK-660-3001

The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically. Participants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.

2023-03-27

2024-10-08

2024-10-08

Active (not recruiting)

Early phase I

37

Inclusion Criteria: 1. Participant and/or legally authorized representative must voluntarily sign a written informed consent form (ICF) after all relevant aspects of the study have been explained and discussed with the Participant. For the participants less than (\<) 18 years old, participants will give assent AND their parents/legally authorized representative should sign the ICF accordingly. 2. Participant and/or legally authorized representative understands and is willing and able to comply with all requirements of the study protocol. 3. Participant should be ethnic Chinese. 4. Participant is 12 to 65 years of age at screening and male. 5. Participant has severe hemophilia A (FVIII clotting activity \<1 percent \[%\]) as confirmed by the central laboratory at screening after a washout period of at least 72 to 96 hours. 6. The last on-demand or prophylactic treatment received is within 3 months before screening. 7. Participant has documented previous treatment with plasma-derived FVIII concentrates or recombinant FVIII for greater than (\>) 150 EDs. 8. Participant is human immunodeficiency virus (HIV)-negative, or HIV-positive with stable disease and CD4+ count greater than or equal to (\>=) 200 cells per cubic millimeter (/mm\^3). 9. Participant is hepatitis C virus (HCV) negative by antibody testing (if positive, additional polymerase chain reaction testing will be performed to confirm), as confirmed at screening; or HCV-positive with chronic stable hepatitis, as assessed by the investigator. Exclusion Criteria: 1. Participant has detectable FVIII inhibitory antibodies (\>=0.6 Bethesda units \[BU\] per milliliter \[/mL\] using the Nijmegen modification of the Bethesda assay) as confirmed by the central laboratory at screening. 2. Participant has a confirmed history of FVIII inhibitory antibodies (\>=0.6 BU using the Nijmegen modification of the Bethesda assay or \>=0.6 BU using the Bethesda assay) at any time prior to screening. 3. Participant has a known hypersensitivity to Adynovate or ADVATE or any of the components of the study drugs, such as mouse or hamster proteins, or other FVIII products. 4. Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (example, qualitative platelet defect or von Willebrand's disease). 5. Participant has severe hepatic dysfunction (example, \>=5 times the upper limit of normal \[ULN\] for alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\], a recent or persistent international normalized ratio \[INR\] \>1.5, as confirmed by the local laboratory at screening). 6. Participant has severe renal impairment (serum creatinine \>1.5 times the ULN) as confirmed by the local laboratory at screening. 7. Participant is planned or likely to undergo major surgery during the study period. 8. Participant has current or recent (\<30 days) use of other PEGylated drugs before study participation or scheduled use of such drugs during study participation. 9. Participant has received emicizumab therapy within 6 months of screening. 10. Participant is currently receiving, or scheduled to receive during the study, an immunomodulating drug (example, systemic corticosteroid agent at a dose equivalent to hydrocortisone \>10 milligram per day \[mg/day\], or alpha-interferon) other than antiretroviral chemotherapy. 11. Participant has participated in another clinical study involving the use of an investigational product (IP) other than Adynovate or an investigational device within 30 days before the screening visit or is scheduled to participate in another clinical study involving an IP or investigational device during this study. 12. Participant has a medical, psychiatric, or cognitive illness or recreational drug/alcohol use that, in the opinion of the investigator, would affect participant safety or compliance. 13. Participant, in the opinion of the investigator, is unable or unwilling to comply with the study protocol.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 37, 'type': 'ACTUAL'}}

2024-04-05